Mylan to buy injectable drugs unit of Strides for $1.6 billion

Thu Feb 28, 2013 4:50am IST

Related Topics

Stocks

   

REUTERS - Generic drugmaker Mylan Inc (MYL.O) said it would buy the injectable drugs unit of Strides Arcolab Ltd (STAR.NS) for $1.6 billion to expand its presence in the fast-growing generic injectables market.

The deal for Agila Specialities, a wholly-owned subsidiary of Strides, caps months of uncertainty regarding its sale, with reports suggesting Pfizer Inc (PFE.N) and Japan's Otsuka Holdings Co Ltd as other potential buyers.

The deal will help Mylan, one of the world's largest generic drugmakers, double its injectable drugs portfolio.

A raft of patent expiries that will stretch until 2016 is expected to drive growth in the global generic injectables market. Also, many generic injectable drugs, which tend to be administered in hospitals, have been in short supply in the United States, including treatments for cancer.

"Together we will have more than 700 marketed injectables products and a global pipeline of more than 350 injectables products pending approval," Mylan President Rajiv Malik said.

Mylan said the acquisition of Bangalore-based Agila is expected to immediately add to its adjusted diluted earnings per share following closing.

"We expect the transaction to have a greater than 10 percent return on invested capital by the third full year from closing," CFO John Sheehan said in a conference call.

Mylan will also pay Strides Arcolab $250 million in potential milestone payments, it said.

Mylan said it will not assume any outstanding debt for the deal, which was unanimously approved by its board.

Separately, Mylan reported a 25 percent rise in fourth-quarter results profit, helped by sales of its Epipen auto-injector for the treatment of severe allergic reactions.

Mylan's shares were up 2 percent in extended trading after closing at $28.57 on Wednesday on the Nasdaq.

(Reporting By Adithya Venkatesan and Vrinda Manocha in Bangalore; Editing by Saumyadeb Chakrabarty)

FILED UNDER:
  • Most Popular
  • Most Shared

Coal

REUTERS SHOWCASE

Kotak-ING Deal

Kotak-ING Deal

Kotak Mahindra to acquire ING Vysya Bank  Full Article 

Ranbaxy in U.S.

Ranbaxy in U.S.

U.S. court overturns bid by Ranbaxy to block launch of rival generic drugs.  Full Article 

Edible Oil

Edible Oil

Indians get taste for branded edible oil as prices drop, incomes rise.  Full Article 

Financial Tech CEO

Financial Tech CEO

Financial Tech founder steps down as CEO   Full Article 

Canpotex Deal

Canpotex Deal

Canpotex signs potash sales deals to India  Full Article 

Tech Acquisition

Tech Acquisition

Tech Mahindra to buy U.S.-based network services operator for $240 million   Full Article 

Fired for Overbilling

Fired for Overbilling

Infosys unit's overbilling Apple led to exit of top execs - sources.  Full Article 

Real Estate Investment

Real Estate Investment

JM Financial subsidiary gets $87 mln from Vikram Pandit-led fund  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage